BackAnthera Pharmaceuticals Overview

Anthera Pharmaceuticals Long Term Debt

Anthera Pharmaceuticals's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Anthera Pharmaceuticals Long Term Debt History

Loading

Anthera Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Anthera Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Anthera Pharmaceuticals (ANTH) FAQ

The latest long-term debt for ANTH is $0 as of March 2018. In the prior-year period, the figure was $0. Investors often review this figure alongside Anthera Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANTH's long-term debt moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Anthera Pharmaceuticals's operating scale or balance-sheet position.

A long-term debt figure of $0 for ANTH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ANTH's long-term debt ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Anthera Pharmaceuticals's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.